Responder-derived FMT (R-FMT) and Pembrolizumab in Relapsed/Refractory PD-L1 Positive NSCLC
Status:
Not yet recruiting
Trial end date:
2026-07-01
Target enrollment:
Participant gender:
Summary
This study is to determine if a fecal microbiota transplant (FMT) improves the body's ability
to fight cancer in patients with relapsed/refractory PD-L1 Positive NSCLC.